Search results for " Thera"

showing 10 items of 9818 documents

A Stage-Based Approach to Therapy in Parkinson’s Disease

2019

Parkinson’s disease (PD) is a neurodegenerative disorder that features progressive, disabling motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances, and cognitive impairment can present, and they often become a heavy burden for both patients and caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and non-phar…

0301 basic medicinemedicine.medical_specialtyParkinson's diseaseImpulse control disorderlcsh:QR1-502ReviewDiseasel-dopaBiochemistryREM sleep behavior disorderMotor symptomslcsh:MicrobiologyAntiparkinson Agentsnon-pharmacological therapy03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationmedicineHumansdopamine-agonistsApathyanticholinergicsResting tremorMolecular Biologyamantadinebusiness.industryAmantadineParkinson Diseasemonoamine oxidase inhibitorsmotor symptomsmedicine.diseasenon-motor symptoms030104 developmental biologyacetylcholinesterase inhibitorsParkinson’s disease<span style="font-variant: small-caps">l</span>-dopaSettore MED/26 - Neurologiamedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugBiomolecules
researchProduct

Interstitial lung disease in systemic sclerosis: current and future treatment.

2017

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc–ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis,…

0301 basic medicinemedicine.medical_specialtyPathologyFibrosiImmunologyInterstitial lung diseaseSclerodermaPulmonary function testingSclerodermaPathogenesis03 medical and health sciencesSystemic sclerosi0302 clinical medicineRheumatologyFibrosisPredictive Value of TestsRisk FactorsInternal medicineCase fatality ratemedicineAnimalsHumansImmunology and AllergyMolecular Targeted Therapyskin and connective tissue diseasesLungCause of death030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterstitial lung diseaseHematopoietic Stem Cell Transplantationrespiratory systemmedicine.diseaseRheumatologyRespiratory Function Testsrespiratory tract diseasesTreatmentSettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisTreatment OutcomebusinessLung Diseases InterstitialTomography X-Ray ComputedImmunosuppressive AgentsLung Transplantation
researchProduct

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

2017

Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.

0301 basic medicinemedicine.medical_specialtyPathologyReceptor Platelet-Derived Growth Factor alphamedicine.medical_treatmentPDGFR-αAntineoplastic AgentsTargeted therapy03 medical and health sciences0302 clinical medicineGrowth factor receptorDoxorubicin; Olaratumab; PDGFR-α; Soft tissue sarcomas; Hematology; Oncology; Geriatrics and GerontologyInternal medicinemedicineHumansDoxorubicinOlaratumabSoft tissue sarcomaHematologybiologybusiness.industryAntibodies MonoclonalCancerSoft tissueSarcomaHematologySoft tissue sarcomasmedicine.disease030104 developmental biologyOncologyDoxorubicin030220 oncology & carcinogenesisbiology.proteinGeriatrics and GerontologybusinessPlatelet-derived growth factor receptormedicine.drugOlaratumab
researchProduct

Clinical whole-exome sequencing for the diagnosis of rare disorders with congenital anomalies and/or intellectual disability: substantial interest of…

2017

International audience; PurposeCongenital anomalies and intellectual disability (CA/ID) are a major diagnostic challenge in medical genetics—50% of patients still have no molecular diagnosis after a long and stressful diagnostic “odyssey.” Solo clinical whole-exome sequencing (WES) was applied in our genetics center to improve diagnosis in patients with CA/ID.MethodsThis retrospective study examined 416 consecutive tests performed over 3 years to demonstrate the effectiveness of periodically reanalyzing WES data. The raw data from each nonpositive test was reanalyzed at 12 months with the most recent pipeline and in the light of new data in the literature. The results of the reanalysis for …

0301 basic medicinemedicine.medical_specialtyPediatricsCongenital anomaliesIntellectual disabilityTranslational researchClinical WES dataCongenital Abnormalities03 medical and health sciencesRare DiseasesIntellectual disabilityDatabases GeneticExome SequencingmedicineHumansExomeGenetic Testing[ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human geneticsExomeGenetics (clinical)Exome sequencingGenetic testingRetrospective Studiesmedicine.diagnostic_testbusiness.industryHigh-Throughput Nucleotide SequencingRetrospective cohort studySequence Analysis DNAmedicine.diseaseAdditional research3. Good health030104 developmental biology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsWhole-exome sequencingPhysical therapyRaw databusiness
researchProduct

Physical exercise increases adult hippocampal neurogenesis in male rats provided it is aerobic and sustained

2016

Key points Aerobic exercise, such as running, enhances adult hippocampal neurogenesis (AHN) in rodents. Little is known about the effects of high-intensity interval training (HIT) or of purely anaerobic resistance training on AHN. Here, compared with a sedentary lifestyle, we report a very modest effect of HIT and no effect of resistance training on AHN in adult male rats. We found the most AHN in rats that were selectively bred for an innately high response to aerobic exercise that also run voluntarily and increase maximal running capacity. Our results confirm that sustained aerobic exercise is key in improving AHN. Abstract Aerobic exercise, such as running, has positive effects on brain …

0301 basic medicinemedicine.medical_specialtyPhysiologybusiness.industryNeurogenesisPhysical exerciseInterval training03 medical and health sciences030104 developmental biology0302 clinical medicineEndocrinologyEndurance trainingInternal medicinemedicinePhysical therapyAerobic exerciseTreadmillbusinessAnaerobic exercise030217 neurology & neurosurgerySedentary lifestyleThe Journal of Physiology
researchProduct

Trend of Drug Abuse in 2011– 2014 in Italy

2017

Doping, although was born as a medication and not with the purpose of enhancing performance, is a widespread practice in all sports, between amateur and gym-goers. The Italian sports federations were in second place worldwide for positive doping-test, after Russia. This review focuses on the analysis of data collected by Italian National Olympic Committee (CONI) in the 2012&ndash;2014 period, showing that the most commonly used substances were anabolic androgenic agents, glucocorticoids, diuretics and stimulants. Prevention in doping could be a key to limit the damage caused by this harmful practice both, for the physical health and the athlete&rsquo;s moral integrity and anti-doping campai…

0301 basic medicinemedicine.medical_specialtyPhysiologydrug abuse physical health AAS glucocorticoids diuretics stimolantsPhysical Therapy Sports Therapy and Rehabilitationlcsh:Physiology03 medical and health scienceslcsh:GV557-1198.9950302 clinical medicineSettore BIO/10 - BiochimicamedicineOrthopedics and Sports Medicinelcsh:Sports medicinePsychiatrydrug abuselcsh:Sportsbiologyglucocorticoidslcsh:QP1-981AthletesMoral integrityPhysical healthmedicine.diseasebiology.organism_classificationAASdiureticsSubstance abusestimolantsPhysical limitations030104 developmental biologyTourism Leisure and Hospitality ManagementPsychologylcsh:RC1200-1245Amateurhuman activitiesphysical health030217 neurology & neurosurgeryCentral European Journal of Sport Sciences and Medicine
researchProduct

Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases.

2016

Background: Due to the continuing increase of the elderly population in the western countries, the prevalence of the main chronic diseases (obesity, type 2 diabetes and related metabolic disorders, arterial hypertension, vascular damage due to atherosclerotic process, cancer, chronic obstructive pulmonary disease, neurodegenerative diseases, chronic kidney disease, immune-mediated diseases) is increasing. There is incontrovertible evidence that regular physical activity contributes to the primary and secondary prevention of several chronic diseases and is associated with a reduced risk of premature death. Methods: In this review the most prevalent chronic pathologic conditions are discussed…

0301 basic medicinemedicine.medical_specialtyPopulationPsychological interventionType 2 diabetes01 natural sciences03 medical and health sciencesMetabolic DiseasesIntervention (counseling)NeoplasmsDrug DiscoverymedicineAnimalsHumansObesity0101 mathematicseducationIntensive care medicineExercisePhysical activity - Chronic diseasesPharmacologyeducation.field_of_studybusiness.industryCancermedicine.diseaseObesity010101 applied mathematics030104 developmental biologyDiabetes Mellitus Type 2Lifestyle changeChronic DiseasePhysical therapybusinessKidney diseaseMuscle ContractionCurrent pharmaceutical design
researchProduct

149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A…

2018

Abstract Background Patients with hematologic malignancies treated with anticancer immunosuppressive therapies (ITs) are at increased risk of herpes zoster (HZ). In a previous report of this phase 3, observer-blind, multicenter trial (NCT01767467), the adjuvanted recombinant zoster vaccine (RZV) was shown to be immunogenic and well-tolerated in ≥18 years of age patients with hematologic malignancies who completed or were undergoing anticancer IT.1 Here we report end-of-study results from the same trial. Methods Participants were randomized 1:1 to receive 2 doses of RZV or placebo (PL) 1–2 months apart, either ≥10 days before or after a cancer therapy cycle, or 10 days to 6 months after canc…

0301 basic medicinemedicine.medical_specialtyPost hocbusiness.industryImmunogenicityCancer therapyHematologic Neoplasmslaw.invention03 medical and health sciencesAbstracts030104 developmental biology0302 clinical medicineInfectious DiseasesOncologyRandomized controlled triallawA. Oral AbstractsInternal medicineRecombinant DNAMedicineZoster vaccine030212 general & internal medicineAdverse effectbusinessmedicine.drugOpen Forum Infectious Diseases
researchProduct

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

2021

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan&ndash

0301 basic medicinemedicine.medical_specialtyPrognostic factorobesityrenal cell carcinomaMultivariate analysisCabozantinibPrognosiClinical Biochemistrybody mass indexurologic and male genital diseasesGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRenal cell carcinomacabozantinibInternal medicinemedicineOverall survivalIn patientneoplasmsPathologicallcsh:R5-920real-world databusiness.industrybody mass index; cabozantinib; obesity; prognosis; real-world data; renal cell carcinoma; targeted therapymedicine.diseasetargeted therapyfemale genital diseases and pregnancy complications030104 developmental biologychemistry030220 oncology & carcinogenesisprognosislcsh:Medicine (General)businessBody mass indexDiagnostics
researchProduct

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct